Clinical Trial Reports Improved Survival in Metastatic Pancreatic Cancer

A recent clinical trial conducted by Revolution Medicines has yielded promising results for a challenging form of cancer.

The trial compared the daily oral medication daraxonrasib to standard chemotherapy in patients with metastatic pancreatic cancer.

Patients who received daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those who received chemotherapy.

External Commentary

The findings have drawn positive attention from experts in the field.

Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, described the survival data in an email as "very impressive."

Disease Context

The trial focused on a condition noted for its high mortality rate and historically limited treatment options.

Reporting

These trial results were reported by Jason Mast, a general assignment reporter at STAT.